The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive, especially with GLP-1 agonists seeing incredible demand and notable profitability.
These GLP-1 agonists, initially prescribed for obesity and diabetes, are now showing potential in treating diverse conditions, expanding the total addressable market significantly for biotech companies.
The bull case for weight loss drug stocks is strong due to their performance and new market opportunities, indicating great potential for investors on dips.
Eli Lilly's stock has soared over 17% recently, with market capitalization approaching $850 billion, as the company is expected to join the $1 trillion club soon.
Collection
[
|
...
]